INTRODUCTION
============

Cytokinesis, the final stage of cell division, is a highly complex process that cleaves a single cell into two daughter cells following segregation of replicated chromosomes. Failures in cytokinesis give rise to tetraploid cells, which harbor twice the normal chromosomal content. Proliferating tetraploid cells are highly genomically unstable and rapidly accumulate both numerical and structural chromosomal abnormalities ([@B15]; [@B45]; [@B6]). Moreover, tetraploid cells, by virtue of their doubled genomes, are able both to buffer deleterious mutations as they arise and to rapidly acquire beneficial mutations that promote adaptation to stressful environments ([@B12]; [@B44]; [@B45]; [@B8]; [@B40]). Consequently, multiple models have validated the conclusion that genomically unstable tetraploid cells can promote tumorigenesis, and current estimates indicate that ∼40% of human solid tumors pass through a tetraploid intermediate at some stage during their evolution ([@B10]; [@B12]; [@B24]; [@B33]; [@B7]; [@B51]).

To combat the potentially oncogenic effects of tetraploidy, nontransformed cells have evolved mechanisms to limit the proliferation of tetraploid cells ([@B4]; [@B1]; [@B16]; [@B41]; [@B22]). First, it is now known that tetraploid cells activate two core kinases of the Hippo tumor suppressor pathway, LATS1 and LATS2 ([@B13]; [@B25]). Activated LATS1/2 kinases phosphorylate the pro-growth transcriptional co-activators YAP and TAZ, ultimately leading to their cytoplasmic retention and subsequent degradation ([@B34]; [@B13]; [@B30]). Second, tetraploid cells promote the stabilization of p53 through caspase-2- and LATS2-dependent mechanisms that inhibit the activity of the p53 E3 ubiquitin ligase MDM2 ([@B2]; [@B13]; [@B11]). Stabilization of p53 leads to a corresponding increase in the expression of one of its core target genes, *CDKN1A*, which encodes the CDK inhibitor p21. Consequently, tetraploid cells arrest in the G~1~ phase of the cell cycle, after which they commonly senesce ([@B1]; [@B13]; [@B35]).

To facilitate tumorigenesis, tetraploid cells must overcome these barriers to cell proliferation ([@B15]). There are three broad routes through which tetraploid cells are known to regain proliferative capacity. First, they can proliferate if they have a nonfunctional or defective p53/p21 pathway ([@B4]; [@B1]; [@B21]; [@B13]; [@B35]). Indeed, analysis of near-tetraploid tumors in the Cancer Genome Atlas (TCGA) reveals a significant enrichment in *TP53*-inactivating mutations, demonstrating the importance of nonfunctional p53 in the tolerance of tetraploidy ([@B5]). Second, they can regain proliferative capacity through functional impairment of the Hippo tumor suppressor pathway, which leads to a corresponding restoration of YAP activity ([@B13]). Analysis of the Cancer Cell Line Encyclopedia (CCLE) reveals that both YAP overexpression and LATS1/2 deletion are highly enriched in near-tetraploid compared with near-diploid cancer cell lines ([@B13]). Importantly, active YAP is sufficient to promote tetraploid cell proliferation even in the presence of a functional p53 pathway ([@B13]; [@B11]). Finally, they can regain proliferative capability by promoting cyclin D accumulation through hyperactivation of mitogenic signaling, or by amplification of the gene encoding for cyclin D itself ([@B13]; [@B38]; [@B5]). When in excess, cyclin D1 has been shown to inhibit p21 through noncatalytic sequestration, resulting in the formation of cyclin D1/p21 complexes that negate p21-mediated growth inhibition and permit tetraploid proliferation ([@B5]).

While functional impairment of the p53/p21 pathway, reactivation of YAP, or increased mitogenic signaling is sufficient to initiate tetraploid proliferation, it remains unclear how cells initially achieve these growth-promoting adaptations. We hypothesized that overexpression of individual microRNAs (miRNAs) may be one route through which tetraploid cells subtly disrupt these pathways to initially escape G~1~ cell-cycle arrest. miRNAs, which are small noncoding RNAs, function as critical regulators of gene expression by repressing the translation of complementary mRNAs. The complementarity region of miRNAs, known as the seed sequence, is ∼6--8 nucleotides in length and may target multiple sites within the same mRNA and/or simultaneously modulate the translation of hundreds of mRNAs ([@B3]). In this manner, miRNAs can control the regulation of multiple signaling pathways at once. Indeed, deregulation of miRNA expression is a common feature of human cancers, with overexpression observed in a variety of tumors ([@B19]).

In this study, we conducted a genome-wide gain-of-function screen to comprehensively identify individual miRNAs that are sufficient to drive tetraploid proliferation when overexpressed. The results of this screen, detailed herein, establish a list of putative oncogenic miRNAs (oncomiRs), many of which have been implicated in driving tumorigenesis. Importantly, we mechanistically define the pathways these miRNAs modulate to overcome tetraploidy-induced G~1~ arrest.

RESULTS AND DISCUSSION
======================

miRNA screen to identify regulators of tetraploid cell proliferation
--------------------------------------------------------------------

We performed a genome-wide gain-of-function screen to identify individual miRNAs that promote the proliferation of G~1~-arrested tetraploid cells. For this screen, we used diploid, nontransformed retinal pigmented epithelial cells (RPE-1), as they contain an intact p53 pathway and undergo durable G~1~ arrest following cytokinesis failure ([@B13]). RPE-1 cells were engineered to stably express the fluorescence ubiquitination cell-cycle indicator (FUCCI) system. The FUCCI reporter system distinguishes cell-cycle position based on a fluorescence readout, where G~1~ cells exhibit red fluorescence (due to expression of a fragment of Cdt1 fused to m-Cherry) and S/G~2~/M cells exhibit green fluorescence (due to expression of a fragment of Geminin fused to Azami-Green; [@B39]).

To generate G~1~-arrested tetraploid cells for the screen, diploid RPE-1 FUCCI cells were treated with 4 μM dihydrocytochalasin B (DCB), an inhibitor of actin polymerization, for 16 h to inhibit cytokinesis ([@B13]). This treatment induces tetraploidy in ∼60% of cells. Fluorescence-activated cell sorting (FACS) was then used to purify tetraploid cells from diploid cells, as previously described ([@B42]). In brief, cells exhibiting both 4N DNA content and red fluorescence, indicative of G~1~ tetraploids, were collected ([Figure 1A](#F1){ref-type="fig"}). This methodology results in a highly enriched (\>95% pure) tetraploid population ([@B13]). Consistent with previous studies, we found that the isolated tetraploid cells exhibited strong G~1~ cell-cycle arrest. Live-cell imaging revealed that \>80% of all binucleated tetraploid cells failed to enter S-phase over 72 h, as indicated by persistent red fluorescence ([Figure 1, D and E](#F1){ref-type="fig"}). In contrast, the vast majority of isolated diploid cells, which were exposed to the same culture conditions, drug treatments, and FACS as tetraploids, showed continued proliferation, as evidenced by a change from red to green fluorescence indicative of the G~1~--S transition ([Figure 1, D and E](#F1){ref-type="fig"}; [@B13]). As a positive control, small interfering RNA (siRNA)---mediated depletion of p53 was observed to restore proliferation to tetraploid cells ([Figure 1D](#F1){ref-type="fig"}).

![Genome-wide screen to identify miRNAs that promote tetraploid cell proliferation. (A) Protocol for a genome-wide miRNA screen to identify overexpressed miRNAs that promote tetraploid cell proliferation. Adapted from [@B13]. (B) Average *Z*-scores for the ∼800 screened individual miRNAs in the primary screen. The primary screen yielded ∼80 miRNAs hits (green) that were subsequently rescreened. (C) The 23 miRNA hits following secondary screening ranked by average *Z*-score. (D) Still images from a live-cell imaging experiment with RPE-FUCCI cells. Sorted diploids and tetraploids transfected with the indicated siRNA/miRNA are shown at 24, 48, and 72 h. Representative images of mitotic cells for each condition are shown on the right. Microtubules (red), chromosomes (white), centrosomes (green). (E) Quantitation of the percentage of cells that enter S/G~2~ for each condition shown in D over 72 h. Error bars represent mean ± SEM from three separate experiments (*n* = 50 cells counted per experiment), \*\*\* *p* ≤ .001, two-tailed *t* test and one-way analysis of variance (ANOVA).](mbc-29-1682-g001){#F1}

To perform the screen, freshly purified G~1~-arrested binucleated tetraploids were seeded in 96-well plates in triplicate and reverse transfected with a library of ∼880 precursor miRNA mimics to emulate overexpression of endogenous miRNA ([Figure 1A](#F1){ref-type="fig"}). Nontargeting miRNA sequences were used as negative controls, while siRNAs targeting p53 were used as positive controls. At 96 h post--miRNA transfection, all plates were fixed and automated image analysis was used to determine the fraction of tetraploid cells per well that had escaped G~1~ arrest and entered S-phase (as judged by a transition from red to green fluorescence; [Figure 1A](#F1){ref-type="fig"}). For the primary screen, miRNA hits were identified as having a *Z*-score ≥6.0, which was determined from multiple intraplate negative controls. Using this strict criterion, the primary screen identified 81 miRNAs for which overexpression enabled tetraploid cells to escape G~1~ arrest ([Figure 1B](#F1){ref-type="fig"}). To validate and reproduce these hits, each of the 81 miRNAs was then rescreened under the same protocol and manually analyzed. This secondary screen resulted in the identification of 23 miRNAs whose overexpression gave an average *Z*-score value ≥5.0 after both biological replicates, indicating robust escape from G~1~ arrest ([Figure 1C](#F1){ref-type="fig"}). To complement the *Z*-score ranking, we further determined how well each miRNA promoted S-phase entry in tetraploids relative to RNA interference (RNAi) depletion of p53. Remarkably, multiple miRNAs enhanced S-phase entry of tetraploid cells nearly as well as p53 loss, including the top two hits, miR-523-3p and miR191-3p, which essentially mirrored the ability of p53 knockdown to overcome G~1~ arrest in tetraploid cells.

We performed live-cell imaging to confirm that tetraploid cells overcame G~1~ arrest following transfection with several of our strongest miRNA hits ([Figure 1, D and E](#F1){ref-type="fig"}). We also assessed the fraction of tetraploid cells that progressed through the cell cycle and ultimately underwent mitosis (Supplemental Figure S1A). Interestingly, even though all miRNA hits were sufficient to promote G~1~/S transition in tetraploids, not all miRNAs enabled progression to mitosis (Supplemental Figure S1A). As expected, those tetraploid cells that did enter mitosis displayed abnormal multipolar spindles as a consequence of containing supernumerary centrosomes ([Figure 1D](#F1){ref-type="fig"}). Despite these mitotic defects, expression of the top two miRNA hits, miR-523-3p and miR-191-3p, was sufficient to induce multiple rounds of tetraploid cell division (Supplemental Figure S1B). Thus, our data demonstrate that overexpression of individual miRNAs is sufficient to promote tetraploid cell proliferation and to promote the abnormal mitotic spindle assembly that leads to subsequent genome instability ([@B14]; [@B43]).

The majority of miRNA hits hyperactivate mitogenic signaling or impair the p53/p21 pathway
------------------------------------------------------------------------------------------

As an initial assessment, we performed cluster analysis to identify whether any of the miRNA hits share seed sequence homology. This analysis revealed that over half of the miRNAs share a recently identified oncomotif seed sequence, AAGUGC (Supplemental Figure S1C). Previous work has demonstrated that miRNAs with an AAGUGC seed motif act as oncomiRs by targeting multiple tumor suppressors to promote the proliferation of cancer cells ([@B56]). Thus, this result validated our screening approach and revealed that many clinically relevant oncomiRs may act, at least in part, by promoting the proliferation of tetraploid cells.

We then sought to identify the specific pathways that are disrupted by overexpression of the strongest miRNA hits. Previous studies have demonstrated that hyperactivation of mitogenic signaling is sufficient to promote tetraploid cell proliferation; therefore, we investigated whether any of our miRNA hits enhanced MAPK or PI3K signaling. To do this, RPE-1 cells transfected with scrambled or endogenous miRNA mimics were serum-starved for 24 h to turn off mitogenic pathways and then restimulated with 5% fetal bovine serum (FBS). Following restimulation, both MAPK and PI3K pathway activation were assessed by quantitating phosphorylated ERK as a fraction of total ERK and phosphorylated AKT as a fraction of total AKT (Supplemental Figure S1, D and E). Results from this assay revealed that overexpression of miR-191-3p, the second strongest hit, significantly stimulates both the MAPK and PI3K pathways and leads to a corresponding increase in cyclin D and cyclin E protein levels in both diploid and tetraploid cells ([Figure 2, A and B](#F2){ref-type="fig"}, and Supplemental Figures S1, D and E, and S2D). Furthermore, we found that miR-191-3p overexpression not only hyperactivates the initial mitogenic response to serum, but also maintains a prolonged activation of MAPK and PI3K signaling over multiple hours ([Figure 2A](#F2){ref-type="fig"}). Owing to its overexpression in 16 different cancer subtypes, miR-191-3p is largely classified as an oncogenic miRNA ([@B9]; [@B32]). Our data reveal that the strong and enduring increase in mitogenic signaling induced by miR-191 overexpression may underpin its capacity to promote tetraploid cell cycle progression, and offer a mechanistic explanation for its frequent overexpression in human cancers.

![miRNA hits increase mitogenic signaling and/or disable the p53/p21 pathway. (A) Representative Western blot of RPE-1 cells, transfected with either a control siRNA (si-C) or miR-191-3p, and serum starved for 24 h prior to restimulation for the indicated time with 5% FBS. (B) Representative Western blot of RPE-1 cells, transfected with either a nontargeting miRNA control (miR-NC) or miR-191-3p, and serum starved for 24 h prior to restimulation with 5% FBS for the indicated duration. (C) Representative Western blot of RPE-1 cells, transfected with the indicated siRNA/miRNA, and treated with or without 100 ng/ml doxorubicin for 4 h. (D) Representative fixed images of RPE-1 cells, transfected with the indicated siRNA/miRNA, and treated with or without 100 ng/ml doxorubicin for 4 h prior to fixation. (E) Normalized fluorescence intensity quantification of images in D. Error bars represent mean ± SEM (*n* \> 650 cells/condition from one experiment), \*\*\*\**p* ≤ 0.0001 and ns = nonsignificant, two-tailed *t* test and one-way ANOVA.](mbc-29-1682-g002){#F2}

In addition to hyperactive mitogenic signaling, abrogation of the p53/p21 signaling axis is also known to restore proliferation to tetraploid cells ([Figure 1E](#F1){ref-type="fig"}; [@B1]; [@B12]; [@B13]). Thus, we investigated whether overexpression of any of the strongest miRNA hits disrupts p53-induced increases in p21 protein (Supplemental Figure S2, A and B). In normal RPE-1 cells, endogenous levels of p53 and p21 are quite low, making detection of decreases in their protein levels difficult. To address this, control cells or cells transfected with miRNA hits were first treated with 100 ng/ml of the DNA-damaging agent doxorubicin for 4 h to induce the p53/p21 pathway. In control cells, this treatment strongly activated p53 and elicited a threefold increase in p21 protein levels ([Figure 2, C--E](#F2){ref-type="fig"}). Using this approach, we identified that our strongest overall hit, miR-523-3p, significantly reduces p21 protein levels in both diploid ([Figure 2, C--E](#F2){ref-type="fig"}, and Supplemental Figure S2, A and B) and tetraploid (Supplemental Figure S2C) cells. This effect is likely to be indirect, as bioinformatics approaches do not strongly predict miR-523-3p to target the 3′ untranslated region of *CDKN1A* mRNA, which we then confirmed with luciferase assays (unpublished data). Thus, our data reveal that disruption of normal p53/p21 signaling by overexpression of individual miRNAs is another route through which tetraploid cells can escape cell-cycle arrest.

Overexpression of miR-24-3p strongly promotes YAP activation and tetraploid cell proliferation
----------------------------------------------------------------------------------------------

Functional inactivation of the Hippo tumor suppressor pathway, which leads to YAP activation, is also known to confer proliferative ability on tetraploid cells ([@B13]). Therefore, we explored whether overexpression of any miRNA hits is sufficient to increase YAP activity. To do this, we quantitated YAP localization in cells transfected with miRNA hits as an indirect readout of its activity, as it is known that YAP is predominantly cytoplasmic (inactive) upon Hippo pathway activation, but predominantly nuclear (active) upon Hippo pathway inactivation ([@B34]; [@B49]). Utilizing this assay, we identified two miRNAs (miR-24-3p and miR-553) that significantly increase nuclear YAP localization relative to controls, indicative of Hippo pathway attenuation ([Figure 3, A and B](#F3){ref-type="fig"}, and Supplemental Figure S3A). Interestingly, miR-24-3p overexpression results in more nuclear-localized YAP than even RNAi-mediated depletion of the kinases LATS1/2, which served as the positive control in this assay. This finding was reproduced in tetraploid RPE-1 cells as well as in HEK293A cells, a cell line frequently employed to study Hippo signaling (Supplemental Figures S2E and S3, B and C; [@B27]; [@B31]). In contrast to overexpression of miR-523-3p, overexpression of miR-24-3p did not abrogate the p53/p21 pathway, nor did it activate mitogenic signaling like miR-191-3p ([Figure 2C](#F2){ref-type="fig"} and Supplemental Figure S1D).

![miR-24 overexpression promotes YAP activation. (A) Relative localization of YAP in RPE-1 cells following transfection with the indicated siRNA/miRNA. Plot depicts the normalized ratio of YAP immunofluorescence intensity in the nucleus:cytoplasm (N/C) performed in triplicate (*n* = 3). Error bars represent mean ± SEM (*n* \>200 cells/condition, \*\*\*\**p* ≤ 0.0001, one-way ANOVA). (B) Representative fixed images of YAP localization in RPE-1 cells 48 h posttransfection with miR-24-3p or negative control (*n* \> 3). (C) Gene-set enrichment analysis of RPE-1 cells transfected with miR-24-3p compared with RPE-1 cells expressing YAP-5SA and two YAP dependent gene-sets. For reference: [@B36], [@B52].](mbc-29-1682-g003){#F3}

To examine whether the observed increase in nuclear YAP from miR-24-3p overexpression led to a corresponding increase in the transcription of YAP-regulated target genes, we performed gene expression analysis. We compared the gene expression profiles of three cell lines: control RPE-1 cells, RPE-1 cells overexpressing miR-24-3p, and RPE-1 cells expressing a constitutively active version of YAP in which five serines phosphorylated by LATS are mutated to alanines (YAP-5SA; [@B55]). Gene set enrichment analysis (GSEA) of the resultant expression data confirmed that YAP-target genes, as defined by the RPE-1 YAP-5SA cells as well as previously published YAP-dependent gene sets, are significantly up-regulated in RPE-1 cells expressing miR-24-3p ([Figure 3C](#F3){ref-type="fig"}; [@B52]; [@B36]). Thus, our data reveal that overexpression of the miRNA miR-24-3p leads to YAP activation.

miR-24-3p overexpression results in down-regulation of the tumor suppressor *NF2*
---------------------------------------------------------------------------------

We aimed to identify potential targets of miR-24-3p to elucidate how it impairs the Hippo pathway to activate YAP. First, we assessed the effect of miR-24-3p overexpression on the levels of the best-characterized Hippo pathway components (e.g., LATS1, LATS2, MST1, MST2; Supplemental Figure S3D). However, none of the core Hippo kinases was down-regulated, due to miR-24-3p overexpression. We then focused our attention on gene expression data, where we found that an upstream activator of the Hippo pathway, the tumor suppressor gene Neurofibromin 2 (*NF2*), was one of the 50 most down-regulated genes upon miR-24-3p overexpression (Supplemental Figure S3E). Known as Merlin in *Drosophila*, NF2 promotes activation of the LATS1/2 kinases, resulting in the phosphorylation and subsequent cytoplasmic sequestration of YAP ([@B28]). Loss of NF2 reduces Hippo pathway activity and promotes active, nuclear YAP ([@B48]; [@B31]; [@B26]). This led us to test whether miR-24-3p overexpression activates YAP through down-regulation of *NF2*.

Consistent with our expression data, we found that miR-24-3p overexpression results in a greater than 50% decrease in NF2 protein levels ([Figure 4, A and B](#F4){ref-type="fig"}). To compare relative YAP activation between miR-24-3p overexpression and depletion of NF2, we performed immunofluorescence imaging of YAP localization following treatment with siRNAs targeting NF2. Indeed, RNAi knockdown of NF2 significantly increases nuclear YAP localization; however, the observed effect does not recapitulate the magnitude of increased nuclear YAP localization achieved by miR-24-3p ([Figure 4, C and D](#F4){ref-type="fig"}). These data suggest that miR-24-3p likely targets multiple mRNAs to inactivate the Hippo pathway and promote YAP activity.

![miR-24 activates YAP through down-regulation of *NF2*. (A) Representative Western blot of NF2 protein levels in RPE-1 cells transfected with the indicated siRNA/miRNA after 48 h. (B) Quantification of Western blots in A. Error bars represent mean ± SEM (*n* \> 3, \*\*\**p* ≤ .001, \*\*\*\**p* ≤ .0001, ns = nonsignificant, one-way ANOVA). (C) Representative fixed images of YAP localization in RPE-1 cells transfected with the indicated siRNA/miRNA after 48 h (*n* \> 3). (D) Plot depicts the normalized ratio of YAP immunofluorescence intensity in the nucleus:cytoplasm (N/C) from C (*n* \> 450 cells/condition, \*\*\*\**p* ≤ .0001, one-way ANOVA).](mbc-29-1682-g004){#F4}

Previous work has identified multiple roles for miR-24-3p in carcinogenesis. miR-24 is overexpressed in many cancer subtypes (e.g., breast, hepatic, and Hodgkin lymphoma), and its up-regulation promotes cell proliferation through disruption of the cyclin-dependent kinase inhibitors p27^Kip1^ and p16^INK4a^ ([@B18]; [@B17]; [@B20]; [@B23]; [@B50]). Interestingly, small-RNA sequencing has revealed several miRNAs that are highly overexpressed in patient hepatocellular carcinoma (HCC) samples relative to cirrhotic nodules, including miR-24-3p with a more than sevenfold increase in expression ([@B47]). This is relevant since hepatocytes from adult animals are predominantly tetraploid, and YAP activation has been shown to promote their proliferation in vivo and encourage the development of HCC ([@B53]; [@B54]; [@B13]; [@B37]). As such, our data suggest that miR-24-3p overexpression in tetraploid hepatocytes may promote cell-cycle progression through activation of YAP, thus providing one potential explanation for this clinical observation.

Summary
-------

We have identified 23 miRNAs whose expression enables tetraploid cells to escape G~1~ arrest and reenter the cell cycle. We have demonstrated that these miRNAs promote tetraploid cell proliferation by either hyperactivating mitogenic signaling, disrupting the p53/p21 pathway, or functionally impairing the Hippo tumor suppressor pathway to activate YAP. As miRNAs are known to have multiple targets, it is likely that simultaneous modulation of several genes by each miRNA combines to induce the strong phenotypic effects observed. Our data suggest that subtle modulation of miRNA expression levels, even transiently, provides routes through which tetraploid cells can overcome cell-cycle arrest and regain proliferative capacity. As proliferating tetraploids are highly genomically unstable, this initial proliferative push may set in motion a subsequent series of mutational events that ultimately lead to tumorigenesis.

MATERIALS AND METHODS
=====================

Cell culture
------------

Telomerase-immortalized RPE-1 cells (American Type Culture Collection) and all derivative cell lines generated in this study were grown in phenol red--free DMEM:F12 containing 10% FBS, 100 IU/ml penicillin, and 100 μg/ml streptomycin. All cells were maintained at 37°C under 5% CO~2~ atmosphere.

Viral infections and siRNA transfections
----------------------------------------

RPE-1 cells were infected for 12--16 h with viruses carrying genes of interest in the presence of 10 μg/ml polybrene, washed, and allowed to recover for 24 h before selection. All siRNA transfections were performed using 50 nM siRNA with Lipofectamine RNAi MAX according to the manufacturer's instructions.

Tetraploid miRNA screen
-----------------------

*Day 1:* Dishes (15 cm) were seeded with 6 million exponentially growing RPE-FUCCI cells, so that they were ∼65% confluent the following day. *Day 2:* DCB (4 μM) was added to each 15-cm dish for 16 h. *Day 3:* DCB-treated cells were washed 5 × 5 min, incubated in medium containing 2.5 μg/ml Hoechst dye for 1 h, trypsinized in 0.05% trypsin, pelleted, resuspended in fresh medium, and FACS sorted. G~1~ diploids (2C DNA content; mCherry^+^, GFP^--^) and G~1~ tetraploids (4C DNA content; mCherry^+^, GFP^--^) were isolated by FACS. Sorted cells were pelleted, resuspended in fresh medium without antibiotics, and replated at a density of 5000 cells per well of a 96-well plate. Cells were then reverse transfected using Lipofectamine RNAi Max (according to the manufacturer's specifications). The final concentration of miRNAs per well was 50 nM. Each plate was screened in triplicate and was internally controlled with multiple p53 siRNA-positive controls and scrambled miRNA negative controls. *Day 4:* All transfected wells were fed with fresh medium containing penicillin/streptomycin. *Day 6:* Monastrol (100 μM) was added to each well for 12 h to arrest proliferating GFP^+^ cells in mitosis. *Day 7:* At 96 h following transfection, cells were fixed with 4% paraformaldehyde. Fluorescence images from each well were acquired using a Nikon TE2000-E2 inverted microscope equipped with a cooled CCD camera (Orca ER, Hamamatsu), and Nikon Perfect Focus. An encoded precision stage was used to capture nine fields of view from each well of the 96-well dish. Subsequently, the total number of proliferating S/G~2~/M cells (based on the GFP positiveness of the FUCCI system) was calculated as a fraction of the total number of cells (based on nuclear counts using Hoechst) for each well. The *Z*-score was calculated using the formula . All miRNAs that had a median *Z*-score of 6.0 were retested in a secondary screen under the same protocol. For the secondary screen, all miRNAs that had a median *Z*-score above 3.0 were manually examined, and any miRNAs that caused cell death or yellow binucleates (indicative of a failure of the FUCCI degradation system) were removed. The *Z*-scores from the two screens were then averaged for each miRNA, resulting in the list of hits.

Immunofluorescence microscopy
-----------------------------

All cells were washed in phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde for 10 min. Cells were extracted in PBS-0.5% Triton X-100 for 5 min., blocked for 30 min in TBS-BSA (10 mM Tris, pH 7.5, 150 mM NaCl, 5% bovine serum albumin \[BSA\], 0.2% sodium azide), and incubated with primary antibodies diluted in TBS-BSA for 30--60 min in a humidified chamber. Primary antibodies were visualized using species-specific fluorescent secondary antibodies (Molecular Probes), and DNA was detected with 2.5 µg/ml Hoechst. Immunofluorescence images were collected on a Nikon Ti-E inverted microscope (Nikon Instruments). Immunofluorescence images of RPE-FUCCI cells, including all data collected from the RNAi screen, were captured on a Nikon TE2000-E2 inverted microscope. Confocal immunofluorescence images were collected on a Nikon Ti-E inverted microscope equipped with a C2+ laser scanning confocal head with 405-, 488-, 561-, and 640-nm laser lines. Images were analyzed using NIS-Elements software and ImageJ. To assess YAP localization, two small boxes were drawn in individual cells: one in the nucleus and one in the cytoplasm. The mean fluorescence intensity of YAP was measured in these regions of interest, and a nuclear:cytoplasmic ratio was determined. All quantifications of YAP fluorescence localization were completed in a blinded manner.

Live-cell imaging
-----------------

RPE-FUCCI cells were grown on glass-bottom 12-well tissue culture dishes (Mattek) and imaged on a Nikon TE2000-E2 inverted microscope equipped with the Nikon Perfect Focus system. The microscope was enclosed within a temperature- and CO~2~-controlled environment that maintained an atmosphere of 37°C and 5% humidified CO~2~. Fluorescence and phase contrast images were captured every 10--20 min with a 10 × 0.5 NA Plan Fluor objective, at multiple points for 2--4 d. All captured images were analyzed using NIS-Elements software.

Protein extraction, immunoprecipitation, and immunoblotting
-----------------------------------------------------------

Cells were washed twice in ice-cold PBS and lysed using ice-cold Laemmli lysis buffer containing HALT (dual phosphatase and protease inhibitor, Thermo Fisher). Lysates were sonicated at 20% amplitude for 20 s, diluted in 4X Sample Buffer (Boston BioProducts), and resolved using SDS gel electrophoresis. Proteins were then transferred onto polyvinylidene difluoride (PVDF) membranes, blocked for 1 h with TBS--0.5% Tween containing 5% skim milk powder, and then probed overnight at 4°C with primary antibodies. Bound antibodies were detected by horseradish peroxidase--linked secondary antibodies and processed with ECL (Amersham) or Clarity ECL (Bio-Rad). Chemiluminescence acquisition was carried out using the Bio-Rad ChemiDox XRS+ system and analyzed using the Bio-Rad Image Lab.

Growth factor restimulation
---------------------------

Control RPE-1 cells, or RPE-1 cells transfected with miRNAs/siRNAs for 48 h, were serum starved overnight; they were then stimulated with medium containing 5% serum for the indicated time points and collected immediately for quantitative Western blot analysis.

Microarray analysis and gene set enrichment analysis
----------------------------------------------------

Total RNA was extracted from exponentially growing control RPE-1 cells (transfected with scrambled siRNA), RPE-1 cells expressing YAP-5SA, and RPE-1 cells transfected with miR-24-3p for 48 h with the RNeasy kit (Qiagen) and hybridized onto Affymetrix HG-U133_Plus_2 arrays per the manufacturer's instructions. GSEA was performed using the GSEA application from the Broad Institute. Analysis was performed using preranked gene lists with phenotype as permutation type, 1000 permutations, and log~2~ ratio of classes as metric for ranking genes ([@B29]; [@B46]). YAP/TAZ dependent gene sets were curated from the following expression data: GSE66083 and GSE54617 ([@B52]; [@B36]).

Reagents and antibodies
-----------------------

The following antibodies were from Cell Signaling Technologies: AKT (\#9272), Phospho-AKT (\#4051), ERK (\#9107), Phospho-ERK (\#9101), LATS1 (\#3477), LATS2 (\#5888 and \#13646), p21 (\#2947), YAP (\#4912), MST1 (\#3682), MST2 (\#3952), NF2 (\#12896), and GAPDH (\#2118). Antibodies against p53 (DO-1), p21 (F-5), Cyclin D1 (A-12), Cyclin E (M-20), MARK2 (H-86) and YAP (63.7) were from Santa Cruz. Antibody against beta-actin (AC-74) was from Sigma. Antibodies against vinculin (ab18058) and AMOTL1 (ab84049) were from Abcam. Doxorubicin and dihydrocytochalasin B were from Sigma.

Plasmids
--------

Plasmids encoding cDNA for YAP-5SA (\#33093) were obtained from Addgene ([@B55]). YAP-5SA was cloned into the pBABE backbone, making use of PCR-based cloning (In-Fusion HD; Clontech).

Statistics
----------

Prism 7 was used for all statistical analyses and for the creation of all graphs.

miRNA and siRNA Sequences
-------------------------

The miRNA library was from Ambion. Accession numbers and sequences for hits are listed in [Table 1](#T1){ref-type="table"}. siRNAs used in this study are listed in [Table 2](#T2){ref-type="table"}.

###### 

Accession numbers and sequences for hits.

  Ambion ID         Human ID          Accession number   Sequence
  ----------------- ----------------- ------------------ --------------------------
  hsa-miR-523       hsa-miR-523-3p    MIMAT0002840       GAACGCGCUUCCCUAUAGAGGGU
  hsa-miR-191\*     hsa-miR-191-3p    MIMAT0001618       GCUGCGCUUGGAUUUCGUCCCC
  hsa-miR-372       hsa-miR-372-3p    MIMAT0000724       AAAGUGCUGCGACAUUUGAGCGU
  mmu-miR-302a      hsa-miR-302a-3p   MIMAT0000684       UAAGUGCUUCCAUGUUUUGGUGA
  hsa-miR-767-5p    hsa-miR-767-5p    MIMAT0003882       UGCACCAUGGUUGUCUGAGCAUG
  hsa-miR-520c-3p   hsa-miR-520c-3p   MIMAT0002846       AAAGUGCUUCCUUUUAGAGGGU
  hsa-miR-302b      hsa-miR-302b-3p   MIMAT0000715       UAAGUGCUUCCAUGUUUUAGUAG
  hsa-miR-302e      hsa-miR-302e      MIMAT0005931       UAAGUGCUUCCAUGCUU
  xtr-miR-148b      hsa-miR-148b-3p   MIMAT0000759       UCAGUGCAUCACAGAACUUUGU
  bta-miR-24        hsa-miR-24-3p     MIMAT0000080       UGGCUCAGUUCAGCAGGAACAG
  hsa-miR-520b      hsa-miR-520b      MIMAT0002843       AAAGUGCUUCCUUUUAGAGGG
  hsa-miR-520a-3p   hsa-miR-520a-3p   MIMAT0002834       AAAGUGCUUCCCUUUGGACUGU
  hsa-miR-302d      hsa-miR-302d-3p   MIMAT0000718       UAAGUGCUUCCAUGUUUGAGUGU
  hsa-miR-520e      hsa-miR-520e      MIMAT0002825       AAAGUGCUUCCUUUUUGAGGG
  hsa-miR-520d-3p   hsa-miR-520d-3p   MIMAT0002856       AAAGUGCUUCUCUUUGGUGGGU
  gga-miR-302c      hsa-miR-302c-3p   MIMAT0000717       UAAGUGCUUCCAUGUUUCAGUGG
  hsa-miR-32        hsa-miR-32-5p     MIMAT0000090       UAUUGCACAUUACUAAGUUGCA
  hsa-miR-298       hsa-miR-298       MIMAT0004901       AGCAGAAGCAGGGAGGUUCUCCCA
  rno-miR-874       hsa-miR-874-3p    MIMAT0004911       CUGCCCUGGCCCGAGGGACCGA
  mmu-miR-200a\*    hsa-miR-200a-5p   MIMAT0001620       CAUCUUACCGGACAGUGCUGGA
  hsa-miR-520g      hsa-miR-520g-3p   MIMAT0002858       ACAAAGUGCUUCCCUUUAGAGUGU
  hsa-miR-553       hsa-miR-553       MIMAT0003216       AAAACGGUGAGAUUUUGUUUU
  hsa-miR-517b      hsa-miR-517b      MIMAT0002857       UCGUGCAUCCCUUUAGAGUGUU

###### 

The siRNAs used in this study.

  Company                  siRNA           Sequence
  ------------------------ --------------- -----------------------
  Dharmacon OnTARGETplus   LATS1-1         GGUGAAGUCUGUCUAGCAA
                           LATS1-2         UAGCAUGGAUUUCAGUAAU
                           LATS1-3         GGUAGUUCGUCUAUAUUAU
                           LATS1-4         GAAUGGUACUGGACAAACU
                           LATS2-1         GCACGCAUUUUACGAAUUC
                           LATS2-2         ACACUCACCUCGCCCAAUA
                           LATS2-3         AAUCAGAUAUUCCUUGUUG
                           LATS2-4         GAAGUGAACCGGCAAAUGC
                           TP53-1          GAAAUUUGCGUGUGGAGUA
                           TP53-2          GUGCAGCUGUGGGUUGAUU
                           TP53-3          GCAGUCAGAUCCUAGCGUC
                           TP53-4          GGAGAAUAUUUCACCCUUC
                           SPINT2-1        GAAGACCACUCCAGCGAUA
                           SPINT2-2        GCAAUAACUUCAUCUAUGG
                           SPINT2-3        CCUGCCAGCUGUUUGUGUA
                           SPINT2-4        CAGCAGGAAUGCAGCGGAU
  Ambion Silencer Select   NF2 (s224112)   AGAUGGAGUUCAAUUGCGATT
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AKT

:   also known as protein kinase B (PKB)

CDKN1A

:   cyclin-dependent kinase inhibitor 1A (p21, Cip1)

ECL

:   enhanced chemiluminescence

ERK

:   extracellular signal-regulated kinase

LATS1

:   large tumor suppressor kinase 1

LATS2

:   large tumor suppressor kinase 2

MAPK

:   mitogen-activated protein kinase

MDM2

:   mouse double minute 2

MST1

:   mammalian STE20-like protein kinase 1 (STK4)

MST2

:   mammalian STE20-like protein kinase 2 (STK3)

PI3K

:   phosphoinositide 3-kinase

YAP

:   Yes-associated protein 1

[^1]: ^†^These authors contributed equally.
